{"id":296218,"date":"2026-03-05T00:00:00","date_gmt":"2026-03-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0002-2024-biopharma-axial-spondyloarthritis-unmet-need-unmet-need-ankylosing-spondylitis-us\/"},"modified":"2026-03-31T10:23:24","modified_gmt":"2026-03-31T10:23:24","slug":"unneim0002-2026-biopharma-axial-spondyloarthritis-unmet-need-unmet-need-ankylosing-spondylitis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0002-2026-biopharma-axial-spondyloarthritis-unmet-need-unmet-need-ankylosing-spondylitis-us-eu\/","title":{"rendered":"Axial Spondyloarthritis &#8211; Unmet Need &#8211; Unmet Need &#8211; Ankylosing Spondylitis (US\/EU)"},"content":{"rendered":"<p>Over the past two decades, <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors (AbbVie\u2019s Humira, Amgen \/ Pfizer\u2019s Enbrel, Johnson &#038; Johnson Innovative Medicine\u2019s Remicade and Simponi, and <abbr title=\"Union Chimique Belge\">UCB<\/abbr>\u2019s Cimzia) have significantly reshaped the treatment landscape for <abbr title=\"ankylosing spondylitis\">AS<\/abbr>, bringing greater focus to this autoimmune disease. <abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors (Novartis\u2019s Cosentyx, Eli Lilly\u2019s Taltz, and <abbr title=\"Union Chimique Belge\">UCB<\/abbr>\u2019s Bimzelx) have further expanded treatment options by offering an alternative mechanism of action. More recently, oral targeted therapies, such as <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors (AbbVie\u2019s Rinvoq and Pfizer\u2019s Xeljanz), have also been approved for <abbr title=\"ankylosing spondylitis\">AS<\/abbr>. This report explores the remaining unmet need in <abbr title=\"ankylosing spondylitis\">AS<\/abbr> treatment and highlights commercial opportunities, as well as the potential for emerging therapies to address these gaps.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals for <abbr title=\"ankylosing spondylitis\">AS<\/abbr>?<\/li>\n<li>Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for <abbr title=\"ankylosing spondylitis\">AS<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr title=\"ankylosing spondylitis\">AS<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new <abbr title=\"ankylosing spondylitis\">AS<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<p>\u2022 Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/p>\n<p>\u2022 Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/p>\n<p>\u2022 Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/p>\n<p><strong>Key feature:<\/strong><\/p>\n<p><abbr title=\"Target Product Profile\">TPP<\/abbr> simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<p><strong>Markets covered: <\/strong>United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European rheumatologists fielded in December 2025<\/p>\n<p><strong>Key companies: <\/strong>AbbVie, Johnson &#038; Johnson Innovative Medicine, <abbr title=\"Union Chimique Belge\">UCB<\/abbr>, Novartis, Eli Lilly, Pfizer<\/p>\n<p><strong>Key drugs:<\/strong> Humira, Remicade, Cimzia, Cosentyx, Taltz, Xeljanz, Rinvoq<\/p>\n","protected":false},"template":"","class_list":["post-296218","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ankylosing-spondylitis","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-therapy-areas-rheumatology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296218\/revisions"}],"predecessor-version":[{"id":575186,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296218\/revisions\/575186"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}